Clinical trial · no report yet · Phase 3
ENZARAD
Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer
- NCT02446444 ↗
- Active not recruiting
- University of Sydney
- 115 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 65 | |
| YouTube | 29 | |
| Podcasts | 21 |
The trial
ClinicalTrials.gov- Official title
- Randomised Phase 3 Trial of Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer: ENZARAD
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Prostatic Neoplasms
- Interventions
- Enzalutamide; Conventional NSAA; LHRHA; External Beam Radiotherapy (78 Gy in 39 fractions or 46 Gy in 23 fractions plus brachytherapy boost)
- Arms
- Enzalutamide · Experimental
- Conventional Non-steroidal Anti-androgen (NSAA) · Active comparator
- Enrollment
- 802
- Primary outcomes
- Metastasis-free survival
- Sponsor
- University of Sydney with Australian and New Zealand Urogenital and Prostate Cancer Trials Group, National Health and Medical Research Council, Australia, Cancer Trials Ireland, Trans Tasman Radiation Oncology Group, European Organisation for Research and Treatment of Cancer - EORTC
- Start
- Mar 2014
- Primary completion
- Jun 2026 (estimated)
- Results posted
- No
- Registry record
- NCT02446444 · updated May 6, 2026